Superior Efficacy With Bortezomib Plus Melphalan–Prednisone (VMP) Versus Melphalan–Prednisone (MP) Alone In Previously Untreated Multiple Myeloma (MM): Results of The Phase III MMY-3002 Vista Study Prof. J. San-Miguel, Spain
- Biography
English - 2008-06-14 Topic: Plasmacell Dyscrasias
Speaker Disclosure
Research Support/P.I.: NA
Employee: NA
Consultant: Millennium; Johnson & Johnson; Celgene; Pharmion
Major Stockholder: NA
Speakers Bureau NA
Honoraria: Johnson & Johnson; Celgene; Pharmion
Scientific Advisory Board: NA
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
- 
